We read with interest the recent article by Mathis et al, 1 which shows that antioxidant therapy reduces blood pressure and albuminuria in an established model of systemic lupus erythematosus (SLE) with associated hypertension. The authors also suggest that, although therapy does not alter SLE disease progression, it does reduce renal oxidative stress. 1 We raise several issues. Reducing proteinuria is a key goal in chronic kidney disease management in the clinic, and this is best achieved by reducing blood pressure.
